

## Special Issue

# Virotherapy and Gene Therapy in Cancer

### Message from the Guest Editor

Recent advancements in oncolytic viral therapy and gene therapy for cancer have shown great potential for improving the survival rates and quality of life of cancer patients. We are excited to announce that our journal is currently accepting original research articles and reviews on a range of topics related to cancer treatment. We cordially invite you to submit your high-quality research articles on any of the following topics:

- Oncolytic and immunomodulatory activity of live attenuated viral vaccines;
- In situ vaccination of immunovirotherapy;
- Radiation therapy combined with oncolytic viral therapy;
- Oncolytic virus design and engineering;
- Viral delivery of therapeutic proteins;
- Cancer gene therapy;
- Minimally invasive Cancer imaging using viral vectors;
- Oncolytic virus delivery;
- Systemic immunovirotherapy combined with immune checkpoint inhibitors;
- Combination natural products and oncolytic viruses;
- Targeting the stroma in Cancer;
- Metastases targeting;
- Combination therapies;
- Combination of cellular therapy and oncolytic viral therapies.

### Guest Editor

Dr. Bolni Marius Nagalo

Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA

### Deadline for manuscript submissions

closed (15 May 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/171929](https://mdpi.com/si/171929)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).